Growth Differentiation Factor 15 expression and regulation during erythroid differentiation in non-transfusion dependent thalassemia

Ronzoni, Luisa; Sonzogni, Laura; Duca, Lorena; Graziadei, Giovanna; Cappellini, Maria Domenica; Ferru, Emanuela

doi:10.1016/j.bcmd.2014.08.006

Cited by 10 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This can be resolved via blood transfusions 19. The increased levels of GDF15 and sTfR indicate ineffective erythropoiesis 20. Consistent with the results of the present study, a previous study reported significantly higher EPO levels in patients with thalassemia compared to normal subjects 18.…”

Section: Discussionsupporting

confidence: 90%

Imbalance of erythropoiesis and iron metabolism in patients with thalassemia

Huang¹,

Yu²,

Liu³

et al. 2019

Int. J. Med. Sci.

View full text Add to dashboard Cite

Aim: This study aimed to evaluate the imbalance of erythropoiesis and iron metabolism in patients with thalassemia.Methods: 192 patients with non-transfusion-dependent thalassemia (NTDT), 94 patients with transfusion-dependent thalassemia (TDT) and 101 healthy controls were recruited between June 2013 and December 2016 in the Hematology Department, the First Affiliated Hospital of Guangxi Medical University. The groups were compared in terms of levels of erythropoiesis biomarkers [growth differentiation factor 15 (GDF15), erythropoietin (EPO) and soluble transferrin receptor (sTfR)] and of iron overload biomarkers [serum ferritin (SF), liver iron concentration (LIC) and cardiac T2*] and hepcidin.Results: The levels of GDF15, EPO, sTfR, LIC and SF were significantly higher in patients with thalassemia. The levels of GDF15 and EPO were significantly higher in patients with TDT compared to NTDT. Those with iron overload had higher EPO, GDF15, SF and sTfR levels compared with non-iron overload patients. Hepcidin levels and ratios of hepcidin to erythropoietic activity and to iron biomarker levels were lower in patients with β-thalassemia intermedia or hemoglobin (Hb) E/β-thalassemia than in patients with HbH disease. The hepcidin levels were correlated negatively with the levels of EPO, GDF15 and sTfR in patients with NTDT and TDT, but correlated positively with SF and Hb levels only in patients with TDT.Conclusions: Patients with thalassemia showed iron overload, reduced hepcidin levels, and a greater extent of ineffective erythropoiesis. The hepcidin levels were more strongly related to ineffective erythropoiesis compared with iron overload. The imbalance between erythropoiesis and iron metabolism differed across different thalassemia types.

show abstract

Section: Discussionsupporting

confidence: 90%

Imbalance of erythropoiesis and iron metabolism in patients with thalassemia

Huang¹,

Yu²,

Liu³

et al. 2019

Int. J. Med. Sci.

View full text Add to dashboard Cite

show abstract

“…These results also suggest that hepcidin synthesis is inappropriately attenuated in patients with HS and HE. The direct signals need to be identified because hepcidin inhibition by EPO is indirect and requires active bone marrow erythropoiesis 13,23,24 and GDF15 is considered a marker of ineffective erythropoiesis rather than the main suppressor of hepcidin 17 . Very promising is the description of an erythroid regulator, named erythroferrone which stimulates hepcidin synthesis in response to chronic bleeding and EPO administration 8 .…”

Section: Discussionmentioning

confidence: 99%

“…This indicates increased erythropoietic activity in the bone marrow of thalassemia carriers and patients with erythrocyte membrane defect. To assess the degree of ineffective erythropoiesis 16,17 , serum growth differentiation factor 15 (GDF15) was measured using ELISA. The mean GDF15 level was increased in both groups (thalassemia carriers, 653 pg/mL; erythrocyte membrane defects, 387 pg/mL) compared to the controls (205 pg/mL), but only in thalassemia carriers did the difference reach statistical significance (Table 2 and Fig.…”

Section: Hematological Data and Erythropoietic Activitymentioning

confidence: 99%

Characterization of iron metabolism and erythropoiesis in erythrocyte membrane defects and thalassemia traits

Sulovska¹,

Holub²,

Zidova³

et al. 2016

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

a Background and Aims. Erythropoiesis is closely related to iron metabolism in a balanced homeostasis. Analyses of diverse erythroid and iron metabolism disorders have shown that disrupted erythropoiesis negatively affects iron homeostasis and vice versa. The aim of this study was to characterize the relationship between erythropoietic activity and iron homeostasis in pediatric patients with erythrocyte membrane defects and thalassemia traits. Methods. Selected markers of erythropoietic activity (erythropoietin, soluble transferrin receptor -sTfR and growth differentiation factor 15) and iron status parameters (serum iron, ferritin and hepcidin) were evaluated in pediatric patients with erythrocyte membrane defects and thalassemia traits. Results. The patients with erythrocyte membrane defects and thalassemia traits had altered iron homeostasis due to disturbed erythropoiesis. In comparison with healthy controls, they had a normal to low hepcidin/ferritin ratio and concomitantly elevated sTfR. Conclusion. The findings suggest that pediatric patients with erythrocyte membrane defects and thalassemia traits are more susceptible to iron overload than the general population and that the (hepcidin/ferritin)/sTfR ratio can be used to monitor any worsening of the disease.

show abstract

“…Additionally, because there was a 1-year time lag between biomarker and echocardiographic measurements, it is possible that we missed associations that would have been observed had they been measured simultaneously. Previous studies have reported possible associations with GDF-15 and anemia [49][50][51][52][53][54][55] ; however, we did not have detailed information on iron stores or other measures of anemia to fully evaluate this association in the present study. This was an observational study, so we cannot determine causality.…”

Section: Discussionmentioning

confidence: 96%

Associations Between Cardiac Biomarkers and Cardiac Structure and Function in CKD

Stein

Zelnick

Anderson

et al. 2020

Kidney International Reports

View full text Add to dashboard Cite

H F is one of the most common cardiovascular complications for persons with CKD, 1 and lower estimated glomerular filtration rate (eGFR) has a graded association with HF development. The pathophysiology of HF is complex in CKD and involves multiple pathways, including inflammation, neurohormonal responses, metabolic and nutritional changes, hemodynamics and fluid status, acid-base changes, and anemia. 2,3 Structural and functional cardiac changes can be appreciated on echocardiography 4 and may precede the development of clinical HF in persons with CKD. Echocardiographic parameters of left ventricular (LV)

show abstract

Growth Differentiation Factor 15 expression and regulation during erythroid differentiation in non-transfusion dependent thalassemia

Cited by 10 publications

References 8 publications

Imbalance of erythropoiesis and iron metabolism in patients with thalassemia

Imbalance of erythropoiesis and iron metabolism in patients with thalassemia

Characterization of iron metabolism and erythropoiesis in erythrocyte membrane defects and thalassemia traits

Associations Between Cardiac Biomarkers and Cardiac Structure and Function in CKD

Contact Info

Product

Resources

About